From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Prediction of outcomes after second-line treatment for acute graft-versus-host disease

Last Updated: Wednesday, June 8, 2022

An examination of overall survival (OS) and failure-free-survival (FFS) of 216 patients who received allogenic hematopoietic cell transplantation and required second-line treatment for acute GvHD had estimated points of OS and FFS at six months of 64% and 46%, respectively.

Blood Advances
Advertisement
News & Literature Highlights
Advertisement
Advertisement